This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Tesla, Meta Platforms & Johnson & Johnson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Meta Platforms, Inc. (FB), and Johnson & Johnson (JNJ).
FATE's Loss Wider Than Expected in Q4, Pipeline in Focus
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the fourth quarter.
Stock Market News for Feb 28, 2022
by Zacks Equity Research
Wall Street closed sharply higher on Friday investors continued to assess the financial risks related to the geopolitical conflict between Russia and Ukraine.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.
Johnson & Johnson (JNJ) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $161.22 in the latest trading session, marking a +0.05% move from the prior day.
Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues
by Zacks Equity Research
Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.
Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22
by Zacks Equity Research
Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Should Value Investors Pick Johnson & Johnson (JNJ) Stock?
by Zacks Equity Research
Let's see if Johnson & Johnson (JNJ) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.
Is Oshares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Drug/Biotech Stock Q4 Earnings Due on Feb 4: BMY, REGN & SNY
by Sundeep Ganoria
Let us take a look at three biotech/pharma companies ¿¿¿ BMY, REGN and SNY ¿¿¿ that are slated to release quarterly results on Feb 4.
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
by Zacks Equity Research
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO
by Indrajit Bandyopadhyay
Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.
The Zacks Analyst Blog Highlights: Apple Inc., Tesla, Inc., and Johnson & Johnson
by Zacks Equity Research
Apple Inc., Tesla, Inc., and Johnson & Johnson are highlighted in this Analyst Blog article.
Top Analyst Reports for Apple, Tesla & Johnson & Johnson
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA), and Johnson & Johnson (JNJ).
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery
by Zacks Equity Research
AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.